Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy as First-line Treatment in Previously Untreated Patients With Unresectable or Metastatic Hepatocellular Carcinoma

NCT07490262 is registered in ClinicalTrials.gov with Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. as lead sponsor.

NCT NCT07490262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07490262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy as First-line Treatment in Previously Untreated Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Lead sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 27, 2026
Completion date
December 31, 2030
Enrollment
680 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)